Swiss National Bank Buys 5,200 Shares of Avantor, Inc. (NYSE:AVTR)

Swiss National Bank boosted its stake in Avantor, Inc. (NYSE:AVTR) by 0.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,016,100 shares of the company’s stock after purchasing an additional 5,200 shares during the period. Swiss National Bank’s holdings in Avantor were worth $52,157,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Avantor during the first quarter worth $159,000. Acadian Asset Management LLC grew its position in Avantor by 45.8% during the 1st quarter. Acadian Asset Management LLC now owns 22,678 shares of the company’s stock worth $579,000 after acquiring an additional 7,120 shares during the last quarter. UniSuper Management Pty Ltd increased its holdings in Avantor by 97.9% in the 1st quarter. UniSuper Management Pty Ltd now owns 9,500 shares of the company’s stock worth $243,000 after purchasing an additional 4,700 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in Avantor by 0.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 553,982 shares of the company’s stock valued at $14,168,000 after purchasing an additional 3,038 shares during the last quarter. Finally, Westwood Holdings Group Inc. boosted its stake in shares of Avantor by 10.5% during the first quarter. Westwood Holdings Group Inc. now owns 723,084 shares of the company’s stock valued at $18,489,000 after purchasing an additional 68,541 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AVTR. Stifel Nicolaus lifted their price target on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Morgan Stanley upped their target price on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, July 29th. TD Cowen raised their price target on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 29th. UBS Group dropped their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, October 8th. Finally, Wells Fargo & Company cut their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.57.

Insider Buying and Selling at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company’s stock.

Avantor Price Performance

Shares of AVTR opened at $20.14 on Thursday. The business’s fifty day moving average is $24.14 and its 200 day moving average is $23.91. Avantor, Inc. has a 12-month low of $19.49 and a 12-month high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The stock has a market cap of $13.71 billion, a P/E ratio of 43.78, a P/E/G ratio of 2.52 and a beta of 1.35.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.